| 1 |
The nuclear receptor superfamily: The second decade
David J. Mangelsdorf, Carl S. Thummel, Miguel Beato et al. · Cell
Open access |
Dec 1995 |
7,017 |
| 2 |
Screening λgt Recombinant Clones by Hybridization to Single Plaques in Situ
W. David Benton, Ronald W. Davis · Science
|
8 Apr 1977 |
4,662 |
| 3 |
Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67.
Johannes Gerdes, Hilmar Lemke, Heinz Baisch et al. · The Journal of Immunology
|
Oct 1984 |
4,236 |
| 4 |
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Scott Arthur Tomlins, Daniel R. Rhodes, Sven Perner et al. · Science
|
27 Oct 2005 |
3,908 |
| 5 |
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Chris C. Parker et al. · New England Journal of Medicine
|
17 Jul 2013 |
3,410 |
| 6 |
The labelling of proteins to high specific radioactivities by conjugation to a 125I-containing acylating agent. Application to the radioimmunoassay
Anthony E. Bolton, W. M. Hunter · Biochemical Journal
Open access |
Jul 1973 |
3,267 |
| 7 |
Studies on Prostatic Cancer: I. The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate
Charles Huggins, Clarence V. Hodges · The Journal of Urology
|
Jul 2002 |
3,204 |
| 8 |
Natural History of Progression After PSA Elevation Following Radical Prostatectomy
Charles R. Pound · JAMA
|
5 May 1999 |
3,112 |
| 9 |
Rapid Isolation of Antigens from Cells with A Staphylococcal Protein A-Antibody Adsorbent: Parameters of the Interaction of Antibody-Antigen Complexes with Protein A
Steven Kessler · The Journal of Immunology
|
Dec 1975 |
2,949 |
| 10 |
Precision Measurement of Half-Lives and Specific Activities of U 235 and U 238
Arthur H. Jaffey, Kian Flynn, L.E. Glendenin et al. · Physical Review C
|
Nov 1971 |
2,874 |
| 11 |
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Oliver A. Sartor, Johann Sebastian De Bono, Kim N. Chi et al. · New England Journal of Medicine
Open access |
23 Jun 2021 |
2,834 |
| 12 |
Metastasis to bone: causes, consequences and therapeutic opportunities
Gregory R. Mundy · Nature reviews. Cancer
Review |
Aug 2002 |
2,802 |
| 13 |
Mechanisms of Bone Metastasis
Garson David Roodman · New England Journal of Medicine
|
14 Apr 2004 |
2,764 |
| 14 |
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis et al. · New England Journal of Medicine
Open access |
3 Sep 2014 |
2,744 |
| 15 |
Efficient Trace-labelling of Proteins with Iodine
Arthur Sproul McFarlane · Nature
|
5 Jul 1958 |
2,560 |
| 16 |
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Paul Gerard Guy Richardson et al. · New England Journal of Medicine
Open access |
15 Jun 2005 |
2,514 |
| 17 |
A rapid radiochemical method for the determination of choline acetyltransferase
Frode Fonnum · Journal of Neurochemistry
|
Feb 1975 |
2,403 |
| 18 |
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study
Michael S. Hofman et al. · The Lancet
|
22 Mar 2020 |
2,053 |
| 19 |
Radioimmunoassay for Cyclic Nucleotides
Alton L. Steiner, Charles W. Parker, DAVID M. KIPNIS · Journal of Biological Chemistry
Open access |
Feb 1972 |
2,032 |
| 20 |
Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands
Robert B. Innis et al. · Journal of Cerebral Blood Flow & Metabolism
|
23 May 2007 |
2,002 |
| 21 |
Metastatic bone disease: clinical features, pathophysiology and treatment strategies
Robert Edward Coleman · Cancer Treatment Reviews
|
Jun 2001 |
1,942 |
| 22 |
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
Himisha Beltran, Davide Prandi, Juan Miguel Mosquera et al. · Nature Medicine
Open access |
8 Feb 2016 |
1,786 |
| 23 |
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
Howard I. Scher et al. · Journal of Clinical Oncology
Open access |
22 Feb 2016 |
1,667 |
| 24 |
A Comparative Study of the Peroxidase-antiperoxidase Method and an Avidin-Biotin Complex Method for Studying Polypeptide Hormones with Radioimmunoassay Antibodies
Su-Ming Hsu, Laurence Raine, Herbert Fanger · American Journal of Clinical Pathology
|
May 1981 |
1,655 |
| 25 |
Bisphosphonates: Mechanism of Action and Role in Clinical Practice
Matthew T. Drake, Bart Lyman Clarke, Sundeep Khosla · Mayo Clinic Proceedings
Open access |
Sep 2008 |
1,648 |
| 26 |
Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients
E. P. Krenning, Dik J. Kwekkeboom, Willem H. Bakker et al. · European Journal of Nuclear Medicine and Molecular Imaging
Open access |
Aug 1993 |
1,572 |
| 27 |
Prostate-specific membrane antigen expression in normal and malignant human tissues.
Donald Silver, Inmaculada Pellicer, W R Fair et al. · PubMed
|
1997 |
1,552 |
| 28 |
Graphical Analysis of Reversible Radioligand Binding from Time—Activity Measurements Applied to [ N - 11 C-Methyl]-(−)-Cocaine PET Studies in Human Subjects
Jean Logan, Joanna S. Fowler, Nora D. Volkow et al. · Journal of Cerebral Blood Flow & Metabolism
|
Sep 1990 |
1,528 |
| 29 |
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
Eugene D. Kwon et al. · The Lancet Oncology
Open access |
12 May 2014 |
1,518 |
| 30 |
In vivo amplification of the androgen receptor gene and progression of human prostate cancer
Tapio Visakorpi, Eija Hyytinen, Pasi A. Koivisto et al. · Nature Genetics
|
Apr 1995 |
1,500 |
| 31 |
Treatment With the Radiolabeled Somatostatin Analog [ 177 Lu-DOTA 0 ,Tyr 3 ]Octreotate: Toxicity, Efficacy, and Survival
Dik J. Kwekkeboom, Wouter W. de Herder, Boen L.R. Kam et al. · Journal of Clinical Oncology
Open access |
29 Apr 2008 |
1,459 |
| 32 |
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
Karim S. Fizazi, Howard I. Scher, Arturo Molina et al. · The Lancet Oncology
|
17 Sep 2012 |
1,402 |
| 33 |
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Charles J. Ryan et al. · The Lancet Oncology
|
15 Jan 2015 |
1,378 |
| 34 |
Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial
Piet Ost, Dries Reynders, Karel Decaestecker et al. · Journal of Clinical Oncology
|
14 Dec 2017 |
1,375 |
| 35 |
Selection of Successive Tumour Lines for Metastasis
Isaiah J. Fidler · Nature New Biology
|
Apr 1973 |
1,368 |
| 36 |
A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity
Thomas Decker, Marie‐Luise Lohmann‐Matthes · Journal of Immunological Methods
|
Nov 1988 |
1,367 |
| 37 |
Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide.
Masashi Mukoyama, Kazuwa Nakao, Kiminori Hosoda et al. · Journal of Clinical Investigation
Open access |
Apr 1991 |
1,363 |
| 38 |
OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine.
Michael G. Stabin, Richard B. Sparks, Eric A. Crowe · PubMed
|
Jun 2005 |
1,356 |
| 39 |
Biodegradable polymers for use in surgery—polyglycolic/poly(actic acid) homo- and copolymers: 1
D.K. Gilding, Andrew M. Reed · Polymer
|
Dec 1979 |
1,341 |
| 40 |
Use of Polyethylene Glycol to Separate Free and Antibody-Bound Peptide Hormones in Radioimmunoassays†
Bernard Desbuquois, G D Aurbach · The Journal of Clinical Endocrinology & Metabolism
|
Nov 1971 |
1,302 |
| 41 |
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
Christopher Parker et al. · The Lancet
Open access |
21 Oct 2018 |
1,289 |
| 42 |
Molecular Imaging with PET
Simon Mensah Ametamey, Michael Honer, Pius August Schubiger · Chemical Reviews
Review |
22 Apr 2008 |
1,274 |
| 43 |
Long-Term Results of the M. D. Anderson Randomized Dose-Escalation Trial for Prostate Cancer
Deborah Ann Kuban, Susan L. Tucker, Lei Dong et al. · International Journal of Radiation Oncology*Biology*Physics
|
4 Sep 2007 |
1,248 |
| 44 |
Monoclonal antibody therapy of cancer
Gregory Paul Adams, Louis M. Weiner · Nature Biotechnology
|
Sep 2005 |
1,246 |
| 45 |
Positron emission tomography provides molecular imaging of biological processes
Michael E. Phelps · Proceedings of the National Academy of Sciences
Open access |
Aug 2000 |
1,243 |
| 46 |
Long-Term Efficacy of Zoledronic Acid for the Prevention of Skeletal Complications in Patients With Metastatic Hormone-Refractory Prostate Cancer
F. Saad, D. M. Gleason, R. Murray et al. · JNCI Journal of the National Cancer Institute
|
Jun 2004 |
1,215 |
| 47 |
Imaging proliferation in vivo with [F-18]FLT and positron emission tomography
Anthony Frank Shields, John R. Grierson, Bernhard Matthias Dohmen et al. · Nature Medicine
|
Nov 1998 |
1,212 |
| 48 |
Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease.
Chantale T. Guy, Marc A. Webster, Michael D. Schaller et al. · Proceedings of the National Academy of Sciences
Open access |
15 Nov 1992 |
1,212 |
| 49 |
Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer
Ryan Phillips et al. · JAMA Oncology
Open access |
26 Mar 2020 |
1,178 |
| 50 |
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
Michael S. Hofman, John A. Violet, Rodney John Hicks et al. · The Lancet Oncology
|
8 May 2018 |
1,178 |